Chugai Pharmaceutical Co., Ltd. announced that it concluded a license agreement with Roche for zilebesiran, an investigational RNAi therapeutic for hypertension created by Alnylam Pharmaceuticals, Inc. and currently under development by Roche and Alnylam.
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
ZURICH, July 24 (Reuters) - Swiss pharmaceutical group Roche (ROG.S) said on Monday it had entered into a partnership with U.S. biopharmaceutical company Alnylam to co-develop and co-commercialise zilebesiran, a therapy to treat hypertension in patients with high cardiovascular risk.